199 related articles for article (PubMed ID: 27090210)
1. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
[TBL] [Abstract][Full Text] [Related]
2. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435
[TBL] [Abstract][Full Text] [Related]
3. A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.
Hamy AS; Bonsang-Kitzis H; Lae M; Moarii M; Sadacca B; Pinheiro A; Galliot M; Abecassis J; Laurent C; Reyal F
PLoS One; 2016; 11(12):e0167397. PubMed ID: 28005906
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer.
Chen Y; Klingen TA; Aas H; Wik E; Akslen LA
J Pathol Clin Res; 2021 Sep; 7(5):517-527. PubMed ID: 34076969
[TBL] [Abstract][Full Text] [Related]
5. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
[TBL] [Abstract][Full Text] [Related]
6. Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype.
Orrù S; Pascariello E; Pes B; Rallo V; Barbara R; Muntoni M; Notari F; Fancello G; Mocci C; Muroni MR; Cossu-Rocca P; Angius A; De Miglio MR
Sci Rep; 2023 Aug; 13(1):12869. PubMed ID: 37553381
[TBL] [Abstract][Full Text] [Related]
7. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
[TBL] [Abstract][Full Text] [Related]
8. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.
Miglietta F; Dieci MV; Giarratano T; Torri V; Giuliano M; Zustovich F; Mion M; Tondini CA; De Rossi C; Bria E; Franchi M; Merlini L; Giannatiempo R; Russo D; Fotia V; Poletti P; Caremoli ER; Arpino MG; De Salvo GL; Zambelli A; Guarneri V
Eur J Cancer; 2023 Dec; 195():113399. PubMed ID: 37950941
[TBL] [Abstract][Full Text] [Related]
9. HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors.
Daemen A; Manning G
Breast Cancer Res; 2018 Jan; 20(1):8. PubMed ID: 29382369
[TBL] [Abstract][Full Text] [Related]
10. Comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
Horimoto Y
Breast Cancer; 2024 Jan; 31(1):154. PubMed ID: 37985622
[TBL] [Abstract][Full Text] [Related]
11. Stromal Tumor-Infiltrating Lymphocytes Associated with Immunohistopathology and Molecular Subtypes of Breast Cancer in Vietnam.
Duong TT; Pham DTN; Duong HNT; Ly TT; Thai TA
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2523-2530. PubMed ID: 37505787
[TBL] [Abstract][Full Text] [Related]
12. PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.
Aswolinskiy W; Munari E; Horlings HM; Mulder L; Bogina G; Sanders J; Liu YH; van den Belt-Dusebout AW; Tessier L; Balkenhol M; Stegeman M; Hoven J; Wesseling J; van der Laak J; Lips EH; Ciompi F
Breast Cancer Res; 2023 Nov; 25(1):142. PubMed ID: 37957667
[TBL] [Abstract][Full Text] [Related]
13. High tumour-infiltrating lymphocytes correlate with distinct gene expression profile and favourable survival in single hormone receptor-positive breast cancer.
Ciarka A; Kunc M; Popęda M; Łacko A; Radecka B; Braun M; Pikiel J; Litwiniuk M; Pogoda K; Iżycka-Świeszewska E; Zeller A; Niemira M; Pęksa R; Biernat W; Senkus E
Contemp Oncol (Pozn); 2024; 28(1):75-83. PubMed ID: 38800535
[TBL] [Abstract][Full Text] [Related]
14. Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2
Debets DO; Stecker KE; Piskopou A; Liefaard MC; Wesseling J; Sonke GS; Lips EH; Altelaar M
Cell Rep Med; 2023 Oct; 4(10):101203. PubMed ID: 37794585
[TBL] [Abstract][Full Text] [Related]
15. Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2024 May; 31(3):536-538. PubMed ID: 38433180
[No Abstract] [Full Text] [Related]
16. The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.
Annaratone L; Cascardi E; Vissio E; Sarotto I; Chmielik E; Sapino A; Berrino E; Marchiò C
Pathobiology; 2020; 87(2):125-142. PubMed ID: 32325459
[TBL] [Abstract][Full Text] [Related]
17. The breast cancer coagulome in the tumor microenvironment and its role in prognosis and treatment response to chemotherapy.
Tinholt M; Tekpli X; Torland LA; Tahiri A; Geisler J; Kristensen V; Sandset PM; Iversen N
J Thromb Haemost; 2024 May; 22(5):1319-1335. PubMed ID: 38237862
[TBL] [Abstract][Full Text] [Related]
18. Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer.
Gonzàlez-Farré M; Gibert J; Santiago-Díaz P; Santos J; García P; Massó J; Bellosillo B; Lloveras B; Albanell J; Vázquez I; Comerma L
Virchows Arch; 2023 Nov; 483(5):655-663. PubMed ID: 37500796
[TBL] [Abstract][Full Text] [Related]
19. Emerging measurements for tumor-infiltrating lymphocytes in breast cancer.
Wu R; Horimoto Y; Oshi M; Benesch MGK; Khoury T; Takabe K; Ishikawa T
Jpn J Clin Oncol; 2024 Jun; 54(6):620-629. PubMed ID: 38521965
[TBL] [Abstract][Full Text] [Related]
20. Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers.
Tseng LM; Huang CC; Tsai YF; Chen JL; Chao TC; Lai JI; Lien PJ; Lin YS; Feng CJ; Chen YJ; Chiu JH; Hsu CY; Liu CY
Transl Oncol; 2023 Dec; 38():101782. PubMed ID: 37713974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
